T he addition of P2Y 12 receptor inhibiting drugs to aspirin therapy has resulted in improved clinical outcome secondary to reduced recurrent ischemic events in patients with acute coronary syndromes (ACS) or after percutaneous coronary intervention (PCI). 1-3 The ischemic benefit is offset by significant morbidity and mortality associated with major bleeding complications in the both coronary artery bypass graft 4 and the nonoperative setting. 5 Indeed, the clinical benefit of systematic pretreatment with P2Y 12 receptor inhibitors (RI) has been recently challenged because of an increase in major Background-Allogenic platelet transfusions (PT) are administered to treat excessive bleeding in patients on P2Y 12 receptor inhibitors (RI). We assessed the effect of ex vivo and in vivo PT on platelet activation and aggregation in patients on dual antiplatelet therapy.
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bleeding risk in non-ST-segment-elevation-ACS patients on prasugrel and a neutral effect with respect to ischemic events in clopidogrel-treated patients where mortality benefit is only seen in ST-segment-elevation myocardial infarction. 6, 7 Acute bleeding represents a major clinical challenge because these drugs do not have a direct antidote. The guidelines proposed treatment for bleeding includes platelet transfusion (PT) based on the hypothesis that replacing the dysfunctional platelet population with functional donor platelets could result in overall improved hemostasis, and indeed this strategy is commonly used in clinical practice. 8, 9 However, the evidence for the efficacy of such a strategy is limited to ex vivo studies with no single evaluation looking at the biological effect of restoration of platelet reactivity after PT in patients who are bleeding in the operative or nonoperative setting, whatever the underlying dual antiplatelet therapy (DAPT) is. [10] [11] [12] [13] [14] Furthermore, no single study has directly compared the effect of transfusion between all 3 P2Y 12 RI: clopidogrel, prasugrel, and ticagrelor.
See Editorial by Sibbing and Massberg
The Antagonize P2Y 12 Treatment Inhibitors by Transfusion of Platelets in an Urgent or Delayed Timing After ACS or PCI Presentation (The APTITUDE study) was designed to examine the ability of PT to restore platelet function in (1) ACS and stable patients loaded with various regimens of P2Y 12 inhibitors (APTITUDE-ACS) with ex vivo autotransfusion and (2) cardiac surgery patients on DAPT with excessive bleeding using conventional in vivo blood bank PT (APTITUDE-Coronary Artery Bypass Graft [CABG] ). The primary objectives were to demonstrate whether PT is effective in restoring platelet function and whether there is a treatment effect with respect to the type of P2Y 12 RI.
Methods

APTITUDE-ACS
Study Population
Between January and August 2012, n=59 patients were recruited at the Heart Institute at Pitié-Salpêtrière University Hospital. Patients were suitable for inclusion in the study if they were for planned coronary angiography or PCI with a loading dose (LD) of clopidogrel 600 mg (group 1), clopidogrel 900 mg (group 2), prasugrel 60 mg (group 3), or ticagrelor 180 mg (group 4) having presented either electively or with an ACS. Those with a personal or family history of bleeding disorders, a platelet count outside the normal range (<150 000 per microliter or >450 000 per microliter), hemoglobin <8 g/dL, current treatment (within 15 days) with another P2Y 12 inhibitor, glycoprotein IIb/IIIa inhibitor NSAID, or poor clopidogrel response were excluded. The institutional ethics committees approved the protocol, and all surviving subjects gave written consent.
Study Design
This was a prospective open-label study. The study design is outlined in Figure 1 . Blood was drawn from participants at 2 different time points; just before administration of the P2Y 12 inhibitor LD (H0) and at 4 hours post loading (H4). Light transmission aggregometry (LTA) was performed at H0 and treatment naïve platelets in the form of platelet-rich plasma (PRP H0) was stored for mixing ex vivo with PRP at H4 (PRP-H4). Increasing proportions of PRP H0 were added as shown in Figure 1B to normalize platelet function.
Aggregation Tests
PRP was obtained by centrifugation of citrated whole blood at 100g for 10 minutes at 20°C. Platelet-poor plasma was obtained by further centrifugation at 4500g for 15 minutes. Ex vivo platelet aggregation in PRP was measured at 37°C by LTA (model 490-4D; Chrono-Log Corp, Kordia, the Netherlands) and was induced by the addition of ADP (Sigma-Aldrich, Saint Quentin Fallavier, France) at final concentrations of 20 µmol/L for clopidogrel, prasugrel, and ticagrelor testing. The measure was performed twice, and the results were expressed in maximal platelet aggregation and residual platelet aggregation (RPA), 6 minutes after induction of aggregation by agonist. Prespecified criteria used to define nonevaluable samples were the lack of sufficient signal, hemolysis, PRP platelet count <150 000 per milliliter and an unstable baseline. 15 
Platelet Transfusion
For APTITUDE-ACS, using the patient's own PRP stored from before loading, increasing proportions of platelets were added by volume ex vivo. To avoid loss of in vitro platelet reactivity, platelet function was measured with LTA at the same time for baseline and autotransfusion samples. In addition, all measurements were performed at least 10 minutes after mixing ( Figure 1 ).
Study End Points and Sample Size
The primary end point of APTITUDE-ACS was the percentage of restoration of platelet reactivity as measured by relative change in RPA to 20 µmol/L ADP (%RPA) after addition of 80% proportion of treatment naïve platelets. The secondary study end point was the absolute change in %RPA after addition of 80% proportion of treatment naïve platelets (H0). Using a pilot study, the sample size for APTITUDE-ACS was calculated to demonstrate that PT would produce 20% lower restoration of platelet reactivity (RPA 80% PT mix/RPA baseline×100) in new P2Y 12 patients (prasugrel 60 and ticagrelor 180) than in clopidogrel patients (clopidogrel 600/900 mg patients); the inclusion of 20 patients per group was required to yield
WHAT IS KNOWN
• The effect of platelet transfusion on platelet function recovery in P2Y 12 RI-treated patients was limited to ex vivo studies without any evidence of the effect of in vivo platelet transfusion in patients with ongoing bleeding.
WHAT THE STUDY ADDS
• Antagonize P2Y 12 Treatment Inhibitors by Transfusion of Platelets in an Urgent or Delayed Timing After Acute Coronary Syndrome or Percutaneous Coronary Intervention Presentation (APTITUDE) demonstrates that the percentage restoration of platelet reactivity after both ex vivo and in vivo platelet transfusion correlates with the strength of platelet inhibition.
• APTITUDE demonstrates that platelet transfusion in P2Y 12 inhibitor-treated patients undergoing surgery with excessive bleeding has a significant and immediate impact on restoration of platelet reactivity.
• This effect is more significant in patients treated with clopidogrel versus those treated with newer generation more potent P2Y 12 RI. 90% power with a significance level of 0.05 and assuming a 20% SD for the difference.
Statistical Analysis
The 4 treatment groups were collapsed to 2 groups for comparison: clopidogrel-treated patients (clopidogrel 600 and 900 mg) and new P2Y 12 inhibitor-treated patients (prasugrel 60 and ticagrelor 180 mg). Continuous variables were expressed as mean±SD unless otherwise stated and categorical variables as frequencies and percentages. Comparisons between the 2 groups were performed by t test for continuous variables and χ 2 or Fisher exact test for categorical variables. Paired t tests were used to compare continuous data obtained before and after loading in the same group. All probabilities with <0.05 were considered statistically significant. Analysis for difference across all 4 groups with respect to RPA 80% PT mix was performed with a 1-way ANOVA.
APTITUDE-CABG
Study Population
Between February 2012 and April 2013, n=54 patients were recruited at Pitié-Salpêtrière University Hospital where >1500 cardiac surgical are performed each year. Patients aged ≥18 years undergoing cardiac surgery while on DAPT and in whom PT was needed urgently to treat uncontrolled or excessive perioperative bleeding irrespective of the underlying type of bleed (Bleeding Academic Research Consortium [BARC] 4 A to C) were recruited. 16 DAPT was defined as a combination of aspirin and a P2Y 12 RI (clopidogrel, prasugrel, or ticagrelor) for at least 5 days as a maintenance dose or 2 days as a maintenance dose after having received the recommended LD with a last maintenance dose taken within the previous 24 hours. Exclusion criteria included treatment with intravenous glycoprotein IIb/IIIa inhibitor therapy within the previous 15 days and any participation in another clinical research study. The institutional ethics committees approved the protocol, and all surviving subjects gave written retrospective consent.
Study Design
This was a prospective open-label study. Blood sampling was performed immediately before (T0) and within 30 minutes of completion of the PT (T1; Figure 2 ). Samples for analysis were drawn from an arterial or central venous catheter connected to a flush system containing 0.9% sodium chloride solution. The first 10 mL drawn was discarded to eliminate the dilution effect of the saline. Blood was collected into Becton-Dickinson (Franklin Lakes, NJ) 3.2% citrate, 60 USP units of Sodium Heparin and K 2 EDTA vacuette tubes.
Laboratory Analyses
The phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) and P-selectin were measured with a Beckman Coulter FC500 cytometer (Beckman Coulter, Villepinte, France) using methods described in the Data Supplement. LTA was performed as described above and the point-of-care assay VerifyNow-P2Y12 according to the manufacturer instructions (Data Supplement). Thromboelastograph analysis TEG with platelet mapping for ADP and arachidonic acid (AA) was performed with the TEG 5000 Thrombelastograph Hemostasis Analyzer system (Haemonetics Corporation, Braintree, MA) using methods described in the Data Supplement.
Surgical Techniques and Definitions
Surgery consisted of CABG, valve surgery (repair or replacement of valve), or complex surgery (multiple valve surgery or CABG with valve surgery or surgery involving the aortic arch; Data Supplement).
Platelet Transfusion
The numbers of standard concentrate units transfused were at the discretion of the surgeon and anesthetist and guided by the recommendations of the French Agency for the Safety of Health Products and the British Committee for Standards in Haematology Guidelines. 9, 17 Transfused platelets concentrates were collected and prepared according to the Council of Europe , and apheresis platelet concentrate or pooled buffy-coat-derived platelet concentrate was used. Blood loss was measured by calculating the volume of mediastinal and pleural drainage for the first 24 hours. The number of units of red blood cells, platelets, fresh frozen plasma, and cryoprecipitate transfused in the operating theater and intensive care units were recorded.
Study End Points and Sample Size
The primary study end point of APTITUDE-CABG was the relative change in VASP measured immediately before (T0) and after in vivo PT (T1) (ΔVASP T1−T0). The secondary study end points were the relative change measured immediately before (T0) and after in vivo PT (T1) as assessed by other platelet function analysis techniques including LTA, VN-PY12, P-Selectin measured by flow cytometry, platelet mapping as assessed by thromboelastograph platelet mapping. 
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Sample size calculation for the APTITUDE-CABG was calculated to demonstrate that PT would lead to 10 absolute differences in the primary end point, ΔVASP (T1−T0), between the clopidogreltreated patients and the novel P2Y 12 RI (prasugrel/ticagrelor); the inclusion of 23 patients per group was required to yield 90% power with a significance level of 0.05 and assuming a 10% SD for the difference.
Statistical Analysis
The primary analysis compared clopidogrel patients with the merged group of new P2Y 12 inhibitor-treated patients (prasugrel and ticagrelor). Continuous variables were expressed as mean±SD unless otherwise stated and categorical variables as frequencies and percentages. Comparisons between the 2 groups were performed by t test for continuous variables and χ 2 or Fisher exact test for categorical variables. For RPA measures, data were included for subjects with evaluable RPA measurements before and after PT. Correlations between platelet storage duration and platelet function data were tested using the Pearson test. All statistical probabilities with <0.05 considered statistically significant. All statistical analysis was performed using GraphPad Prism version 5.00 for Mac (GraphPad Software, San Diego, CA).
Results
APTITUDE-ACS
A total of 59 patients presenting with ACS or for elective angiography±PCI were initially included. Patients with poor pharmacodynamic response to the clopidogrel LD administered (RPA H4>46.6%) were excluded from the final analysis (n=11), as were patients with hemolysed samples (n=3). There were no poor responders to prasugrel or ticagrelor. Fortyfive patients were finally included in the study comprising 4 groups: (1) clopidogrel 600 mg (n=13), (2) clopidogrel 900 mg (n=12), (3) prasugrel 60 mg (n=10), and (4) ticagrelor 180 mg (n=10).
Baseline characteristics between clopidogrel and new P2Y 12 patients (Table 1 ) did not differ apart from a higher of proportion of patients with ACS in the new P2Y 12 -treated patients. Baseline RPA did not differ significantly between groups (P=0.65; Table 2 ; Figure 3 ). The percentage inhibition of platelet aggregation at H4 was more pronounced in prasugrel and ticagrelor patients than in clopidogrel 900 and 600 mg LD patients (95.5±5%, 91.4±7%, 52.5±29%, and 41.1±45.9%, respectively). Platelet mixing with increasing proportions (30%, 50%, and 80%) of baseline treatment naïve platelets (PRP H0) led to a stepwise increase in restoration of platelet reactivity in all groups 1 to 4 (P for trend <0.0001, 0.01, <0.0001, and 0.0052, respectively). The primary end point of percentage restoration of platelet function with 80% proportion PT showed a stepwise decrease from groups 1 to 4 (83.9±11%, 73±14%, 66.3±15%, and 40.9±19%, respectively; P for trend <0.0001).
The absolute increase in %RPA in response to 80% proportion PT was similar in clopidogrel 600 mg and prasugrel 60 mg patients (33.9±12.1% and 34.2±15.6%, respectively), but was significantly less for clopidogrel 900 mg and ticagrelor 180 mg patients (19.2±15.9 and 17.9±9.3, respectively; P=0.02). This was the same when looking at the relative increase ((RPA 80%−RPA 0%)/RPA baseline×100).
APTITUDE-CABG
A total of 54 patients undergoing cardiac surgery who had PT for excessive bleeding were included. The baseline characteristics are outlined in Table 3 . Both patient groups were evenly matched for cardiovascular risks apart from a higher prevalence of type 1 diabetes mellitus in patients treated with newer generation P2Y 12 inhibitors. All patients were on DAPT comprising low-dose aspirin and a maintenance dose of clopidogrel n=43, prasugrel n=6, or ticagrelor n=3. Thirty-three patients were treated with DAPT because of an ACS with or without PCI within the previous year and n=29 because of elective PCI within the previous year. Two thirds of the patients with ACS (n=21) presented within the previous 6 weeks. Patients treated with newer generation P2Y 12 RI were more likely to have a history of recent ACS with a higher proportion presenting with ST-segment-elevation myocardial infarction than those treated with clopidogrel. The operative and transfusion details are outlined in Tables I and II in the Data Supplement. The majority of patients included underwent CABG (n=35), 11.5% had single valve surgery and the remaining patients had complex surgery including cardiac transplantation (n=2), left ventricular assist device implantation (Heartmate II; n=2), and extracorporeal membrane oxygenation (n=1). All except 2 operations were performed on cardiopulmonary bypass (CPB) with post-CPB cell salvage and processing.
PT and Bleeding in APTITUDE-CABG
The decision to transfuse was at the discretion of the cardiothoracic surgeon and anesthetist. All patients were transfused because of excessive intra-and postoperative bleeding, and the transfusion was commenced either just after discontinuation of CPB and administration of protamine sulfate (n=44) or in the immediate postoperative period (<12 hours; n=8). Patients were transfused according to the weight-based guidelines, a mean of 5.5±2.5 concentrate units of platelets (1 U=0.7×10 11 platelets) with the majority transfused with pooled buffy-coat platelets (n=39). No PT reactions occurred. Other products including units of red blood cells, fresh frozen plasma, and fibrinogen were administered, but not at the same time as the PT ( Table II in the Data Supplement) .
Blood volumes from post-CPB cell salvage (Cell Saver) and chest drain volumes are also shown. We found no correlation between mediastinal and pleural drain volume over 24 hours post transfusion and the change in VASP (r=−0.03; P=0.81).
Effect of PT on Platelet Activation
Successful cytometric analysis was achieved in 50 of 54 patients, and the mean baseline (T0) VASP platelet reactivity index was 43±23.3%. When compared with baseline values, transfusion resulted in a relative increase of 23.1% in VASPplatelet reactivity index % (P=0.0003; study primary end point; Figure 4 ). For patients treated with clopidogrel transfusion resulted in a significant relative increase of 34.1% in clopidogrel patients (42.2±23.6% versus 56.6±18.2%; P=0.0008). For patients treated with novel P2Y 12 RI (prasugrel and ticagrelor), there was a relative increase of 24.2% in platelet activation but this did not reach statistical significance (28.1±15.3% versus 34.9±15.3%; P=0.22; Figure 4 ). When comparing the 2 patient groups, the absolute change in VASP-platelet reactivity index % was numerically higher in clopidogrel-treated patients than novel P2Y 12 RI but was not statistically significant (10.4±18.3% versus 6.8±15.2%; P=0.58).
The level of P-selectin expression at rest was subtracted from the raw value of P-selectin expression after activation by ADP to compare the variation in delta of P-selectin expression at baseline and after PT. There was a 7.8% relative increase BMS indicates bare-metal stent; CABG, coronary artery bypass graft; CVD, cerebrovascular disease; DES, drug-eluting stent; LD, loading dose; MI, myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment-elevation myocardial infarction; and UA, unstable angina. All measures were performed at the same time, and mixing was allowed for at least 10 minutes. LD indicates loading dose; and RPA, residual platelet aggregation. Restoration of Platelet Function With Platelet Transfusion in the variation of P-selectin expression after activation with 20 μmol/L thrombin receptor agonist peptide (P=0.016). However, there was no statistically significant change after transfusion when 20 μmol/L ADP and 10 μmol/L ADP was used as antagonist ( Table 4 ).
Table 2. Effects of Ex Vivo Platelet Autotransfusion on Residual Platelet Aggregation as Measured by Light Transmission Aggregation, According to Loading Doses of Various Types of P2Y 12 Receptor Inhibitors
The change in platelet activation measured by VASP did not correlate with clinical parameters known to affect platelet function including age (r=0.07; P=0.71), body mass index (r=0.108; P=0.58), and creatinine clearance (r=0.109; P=0.1). Other factors including diabetes mellitus (P=0.66) and recent myocardial infarction (P=0.62) did not seem to affect the ΔVASP. However, there was a lower but nonsignificant ΔVASP in active smokers (8.58±14.9 versus 17.6±19; P=0.18) and higher ΔVASP in patients with hypertension (15.5±18.2 versus 5.8±16.8; P=0.24).
Effect of PT on Platelet Aggregation
Results of platelet aggregation measured by LTA before and after transfusion in response to ADP are presented in Table 4 . Compared with baseline values, transfusion resulted in a 20.1% relative increase in maximal platelet aggregation but no significant increase in RPA after platelet activation by ADP (P=0.0124 and P=0.87, respectively). There was no significant difference found after activation by AA. There was no significant difference demonstrated with the VerifyNow PM point-of-care assay.
Effect of PT on TEG and Platelet Mapping
Results of global hemostatic parameters by thromboelastograph and platelet mapping before and after the transfusion are detailed in Table 4 . Compared with baseline values, transfusion resulted in increases in 2 of the 4 thromboelastograph curve parameters measured, with a 4.8% increase in the maximal amplitude and a 8.9% increase in the α angle (P=0.042 and 0.018, respectively). With respect to the platelet mapping, there was no significant difference between the parameters with ADP as an agonist. However, PT resulted in a 2-fold increase in maximal amplitude in response to AA; P=0.0002; Table 4 ).
Effect of Platelet Storage Duration and Concentrate Type on Platelet Activation
The median length of conservation of the platelet bags before administration was 3 days (interquartile range, 2-4 days; maximum, 5 days; minimum, 2 days). We found no significant correlation between platelet storage duration and the change in VASP (r=−0.137; P=0.36). Similar results were obtained for maximal platelet aggregation according to LTA (r=−0.04; P=0.85), P-selectin expression with thrombin receptor agonist peptide as the agonist (r=0.526; P=0.053) and the thromboelastograph curve parameters (maximal amplitude: r=−0.32; P=0.19 and angle, r=0.20941; P=0.42). However, we found a significant negative correlation between platelet storage length and the increase in thromboelastograph platelet mapping for aspirin, maximal amplitude AA (r=−0.60; P=0.01), % inhibition AA (r=−0.47; P=0.05) and G AA (r=−0.57; P=0.016).
There was a trend toward higher ΔVASP in patients who were transfused apheresis platelet concentrate versus pooled buffy-coat-derived platelet concentrate, but this did not reach statistical significance (15.4±19.9 versus 7.8±16; P=0.19). There was no association seen between the other markers of platelet activation measured and the type of platelet concentrate transfused. The correlation between number of platelet units transfused and ΔVASP could not be accurately assessed as patients were transfused according to their weight and thus estimated blood volume.
Discussion
In the APTITUDE study, we demonstrate the impact of PT on the normalization of platelet function in both the acute setting post loading in patients for planned PCI (APTITUDE-ACS) and in patients undergoing cardiac surgery (APTITUDE-CABG). First, our main finding was a stepwise increase in platelet aggregation in response to increasing doses of autologous platelets transfused ex vivo in patients loaded with clopidogrel, prasugrel, and ticagrelor. Second, the percentage restoration of platelet reactivity correlated with the strength of platelet inhibition with a less marked overall restoration in the newer P2Y 12 RI. Third, these findings translated to the in vivo model where PT in patients undergoing cardiac surgery with excessive bleeding treated by any of the 3 drugs seemed to have a significant and immediate impact on restoration of platelet reactivity. This was demonstrated with 2 different platelet function testing techniques, including the primary evaluation parameter VASP-platelet reactivity index, a specific marker of P2Y 12 receptor activation. Finally, the impact of PT seems to be more significant in patients treated with clopidogrel versus those treated with newer generation more potent P2Y 12 RI with a trend to higher augmentation of platelet reactivity.
This is the first study to compare all 3 P2Y 12 RIs in the ex vivo setting and to show in vivo biological evidence supporting this commonly used therapy to reverse the effects of P2Y 12 RI therapy in the operative setting. There are, to date, 3 studies examining the effect of platelet supplementation in healthy volunteers or patients on aspirin and clopidogrel. [11] [12] [13] 
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restore platelet reactivity in clopidogrel than in aspirin (50% versus 20% and 90% versus 20%, respectively). [11] [12] [13] Prüller et al 12 supported these findings in an in vivo study of healthy subject treated with aspirin (ASA)+clopidogrel and autologous platelets where there was a modest recovery of P2Y 12 inhibition. The data on PT with newer generation P2Y 12 RI are limited to 2 ex vivo studies. The first, Zafar et al 14 assessed the recovery of platelet function after PRP supplementation in healthy subjects treated with a prasugrel LD; second, where Hansson et al 10 report differences in the functional platelet recovery after ex vivo addition of allogeneic platelets in whole blood samples from patients on ASA, ASA+clopidogrel, or ASA+ticagrelor. Both studies suggest that the efficacy of PT is more modest in patients treated with newer generation P2Y 12 inhibitors.
APTITUDE-ACS supports many of these findings with the added information gained from the direct comparison of all 3 drugs. We confirm and extend the results of Hansson et al 10 by comparing the effects of in vivo PT in patients treated with ASA+clopidogrel versus both newer agents ticagrelor and prasugrel. APTITUDE-CABG extends these observations into the real-world clinical setting where, to date, only anecdotal evidence supports the use of PT to treat bleeding patients on these drugs perioperatively. We demonstrate a significant recovery of platelet function with respect to P2Y 12 receptor pathway (activated by ADP), but this recovery is only modest in comparison with the 2-fold increase in platelet reactivity seen in thromboelastograph platelet mapping examining the AA pathway which aspirin influences. Although not statistically significant, there was a trend toward lower efficacy of PT in patients treated with newer agents. We further add to these findings by showing that thrombin receptor agonist peptide aggregability is also increased, and that overall clotting parameters as evaluated by thromboelastograph are augmented by platelet concentrate transfusion independent of P2Y 12 RI treatment.
Our findings were not consistent across all forms of testing, which may be more a reflection of the limitations of some forms of platelet function analysis in the setting coronary artery bypass graft and CPB. For example, the point-of-care VerifyNow PM assay was not designed for this setting, and LTA was not possible in many cases because of low platelet count and hemolysis of the sample cause by CPB.
There are some limitations to APTITUDE-ACS and APTITUDE-CABG. Because of the exploratory nature of both studies, an accurate sample size calculation could not be conducted. In APTITUDE-ACS, we used the patients own untreated platelets as the donor platelets, which differs somewhat from real-life whereby multiple donors may contribute to a pool of blood bank platelets. However, other study has shown that blood bank platelets have variable platelet function, and so this would have introduced inconsistent effect into this comparison study. 13 In APTITUDE-ACS, there was a higher rate of ACS patients in the prasugrel/ticagrelor group; however, this is unlikely to have contributed to the blunted restoration of platelet reactivity seen in this group because platelet reactivity is higher in ACS presenters. Finally, the 4 hours time delay from platelet aggregation measure to LD may be seen as a bias as it may not have been sufficient for clopidogrel to reach its maximum effect. It was chosen because this was the maximum amount of time that PRP could be stored for autotransfusion. Patients with poor clopidogrel respond 0 20 40 60 80 100
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Clopidogrel Prasugrel or Ticagrelor % VASP-PRI p=0.0003 p=0.2162 p=0.0008 K indicates time to reach an amplitude of 20 mm; MA, maximal amplitude; MPA, maximal platelet aggregation; PRU, platelet reaction unit; R, time to initiate the coagulation cascade; RPA, residual platelet aggregation; and TRAP, thrombin receptor agonist peptide. Restoration of Platelet Function With Platelet Transfusion were excluded to avoid such bias. In the APTITUDE-CABG study, there was no control group of either patients on P2Y 12 RI or naïve of treatment undergoing cardiac surgery with CPB. An effect of improvement in platelet function after discontinuation of CPB regardless of PT cannot be ruled out. However, each patient was its own control, and blood sampling was performed before and directly after the treatment to limit confounding clinical issues. No blood sampling was performed a second time point, and so the possible delayed enhancement of platelet function was not assessed. It should also be acknowledge that patient recruitment was challenging. Indeed, ongoing bleeding on DAPT was a prerequisite, and many patients underwent surgery during off-hours. The limited number of patients may also account for the lack of significant difference in the primary study end point observed in prasugrel-/ticagrelor-treated patients. One cannot rule out a too optimistic sample size calculation because of the lack of previous data on the specific issue of in vivo PT. No definite conclusion could be drawn with respect to the different pharmacological properties of P2Y 12 RI. The inefficacy of PT in reversing the effects of ticagrelor has been reported because circulating ticagrelor and its active metabolite are likely to inhibit the fresh platelets. 18 This is suggested by APTITUDE-ACS trial, but not confirmed in APTITUDE-CABG. Finally, an outcome study would have required a multicenter design.
In conclusion, the APTITUDE study demonstrates that both ex vivo and in vivo PTs in patients exposed to antiplatelet agents have a significant effect on restoration of platelet function. There seems to be a dose-response relationship, and the overall restoration of platelet function depends on the potency of P2Y 12 inhibition. Further larger-scale studies are warranted, especially with newer P2Y 12 RI to correlate the biological with clinical efficacy to further guide management of this treatment group.
